Treatment of Vesicular Aspergillus Infection

Initial Treatment Approach

The Infectious Diseases Society of America recommends voriconazole as the first-line treatment for suspected vesicular Aspergillus infection due to its superior efficacy compared to other antifungal agents, with a loading dose of 6 mg/kg IV every 12 hours for the first 24 hours, followed by a maintenance dose of 4 mg/kg IV every 12 hours 1, 3
Early initiation of antifungal therapy is crucial for improving outcomes in patients with strongly suspected invasive aspergillosis, and treatment should be continued for a minimum of 6-12 weeks, depending on the degree and duration of immunosuppression, site of disease, and evidence of disease improvement 1, 3

Liposomal amphotericin B (3 mg/kg/day IV) is recommended as an alternative first-line agent if voriconazole cannot be tolerated or is contraindicated, based on high-quality evidence from the Infectious Diseases Society of America 1
Isavuconazole is another alternative with a strong recommendation and moderate-quality evidence from the Infectious Diseases Society of America 1
Echinocandins (micafungin or caspofungin) should not be used as primary therapy but can be used when azole and polyene antifungals are contraindicated, as recommended by the Infectious Diseases Society of America 1, 3

Combination antifungal therapy with voriconazole and an echinocandin may be considered in select patients with documented invasive aspergillosis, though this recommendation is based on moderate-quality evidence from the Infectious Diseases Society of America 1, 3

Reducing or eliminating immunosuppressive agents when feasible is advised as a component of anti-Aspergillus therapy, as recommended by the Infectious Diseases Society of America 1
Therapeutic drug monitoring of voriconazole is recommended to ensure adequate drug levels and minimize toxicity, based on evidence from the Infectious Diseases Society of America 3

Regular clinical evaluation of symptoms and signs, radiographic imaging, and serologic assays (when available) should be performed to monitor treatment response, as recommended by the Infectious Diseases Society of America 2

For patients failing initial therapy, an individualized approach is recommended considering the rapidity, severity, and extent of infection, as advised by the Infectious Diseases Society of America 1
Salvage therapy strategies include changing the class of antifungal, reducing immunosuppression when possible, and surgical resection of necrotic lesions in selected cases, based on recommendations from the Infectious Diseases Society of America 1

Delaying antifungal therapy while awaiting diagnostic confirmation can worsen outcomes in high-risk patients, as warned by the Infectious Diseases Society of America 1, 2
Using echinocandins as primary therapy is not recommended due to inferior efficacy compared to voriconazole, as stated by the Infectious Diseases Society of America 1, 3
Failing to monitor drug levels for azole antifungals can lead to suboptimal treatment outcomes or toxicity, as cautioned by the Infectious Diseases Society of America 3